Spots Global Cancer Trial Database for Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors
Official Title: Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy
Study ID: NCT00003304
Conditions
Interventions
Study Description
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients with recurrent oligodendroglial tumors following combination chemotherapy.
Detailed Description: OBJECTIVES: I. Determine the response rate and duration of response in oligodendroglial tumors to temozolomide treatment in patients with progressive disease during or after procarbazine/lomustine/vincristine (PCV) chemotherapy. II. Determine the feasibility and toxicity of temozolomide chemotherapy following PVC chemotherapy in these patients. OUTLINE: This is an open label, multicenter trial. Temozolomide is administered orally on days 1-5 of each 4-week course; treatment continues for a maximum of 12 courses. Patients are followed every 2 months for the first 6 months and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 16-29 patients will be accrued for this study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Kaiser Franz Josef Hospital, Vienna (Wien), , Austria
Hopital Universitaire Erasme, Brussels, , Belgium
Rigshospitalet, Copenhagen, , Denmark
Helsinki University Central Hospital, Helsinki, , Finland
Turku University Central Hospital, Turku, , Finland
Institut Bergonie, Bordeaux, , France
Centre Regional Francois Baclesse, Caen, , France
Hopital Louis Pasteur, Colmar, , France
Centre Hospitalier Universitaire de Bicetre, Le Kremlin Bicetre, , France
Centre Leon Berard, Lyon, , France
CHU de la Timone, Marseille, , France
CHU de Nancy - Hopital Neurologique, Nancy, , France
CRLCC Nantes - Atlantique, Nantes-Saint Herblain, , France
Hopital Pasteur, Nice, , France
Centre Antoine Lacassagne, Nice, , France
C.H.R. de Nimes - Hopital Caremeau, Nimes, , France
CHU Pitie-Salpetriere, Paris, , France
Institut Gustave Roussy, Villejuif, , France
Universitaetsklinikum Benjamin Franklin, Berlin, , Germany
Neurologische Klinik der Henriettenstiftung, Hannover, , Germany
Universitaetsklinikum Tuebingen, Tuebingen, , Germany
National Institute of Neurosurgery, Budapest, , Hungary
Azienda Ospedaliera di Padova, Padova (Padua), , Italy
Universita Degli Studi di Torino, Torino, , Italy
Academisch Ziekenhuis der Vrije Universiteit, Amsterdam, , Netherlands
Antoni van Leeuwenhoekhuis, Amsterdam, , Netherlands
Academisch Ziekenhuis Groningen, Groningen, , Netherlands
Academisch Ziekenhuis Maastricht, Maastricht, , Netherlands
St. Radboud University Hospital, Nijmegen, , Netherlands
Rotterdam Cancer Institute, Rotterdam, , Netherlands
St. Elisabeth Ziekenhuis, Tilburg, , Netherlands
Dr. Bernard Verbeeten Instituut, Tilburg, , Netherlands
Academisch Ziekenhuis Utrecht, Utrecht, , Netherlands
Instituto Portugues de Oncologia de Francisco Gentil, Lisbon, , Portugal
Umea Universitet, Umea, , Sweden
Western General Hospital, Edinburgh, Scotland, United Kingdom
Beatson Oncology Centre, Glasgow, Scotland, United Kingdom
Contact Details
Name: Martin J. van Den Bent, MD
Affiliation: Daniel Den Hoed Cancer Center at Erasmus Medical Center
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
